These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 28817997

  • 1. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K.
    Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P.
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [Abstract] [Full Text] [Related]

  • 3. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 4. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.
    Clin Ther; 2014 Dec 01; 36(12):1958-1971. PubMed ID: 25315404
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 01; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 6. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct 01; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May 01; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 9. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
    Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Adv Ther; 2020 Jan 01; 37(1):225-239. PubMed ID: 31701485
    [Abstract] [Full Text] [Related]

  • 10. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ.
    Neurodegener Dis Manag; 2021 Apr 04; 11(2):99-111. PubMed ID: 33517769
    [Abstract] [Full Text] [Related]

  • 13. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Jack D, Vermersch P.
    Neurodegener Dis Manag; 2022 Dec 04; 12(6):295-301. PubMed ID: 36017780
    [Abstract] [Full Text] [Related]

  • 14. Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.
    Novakovic AM, Krekels EH, Munafo A, Ueckert S, Karlsson MO.
    AAPS J; 2017 Jan 04; 19(1):172-179. PubMed ID: 27634384
    [Abstract] [Full Text] [Related]

  • 15. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
    Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A.
    Neurodegener Dis Manag; 2022 Dec 04; 12(6):303-310. PubMed ID: 36017797
    [Abstract] [Full Text] [Related]

  • 16. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A.
    Mult Scler; 2022 Jan 04; 28(1):111-120. PubMed ID: 33969750
    [Abstract] [Full Text] [Related]

  • 17. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr 04; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 18. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar 04; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 19. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E.
    Mult Scler; 2023 Dec 04; 29(14):1808-1818. PubMed ID: 37978852
    [Abstract] [Full Text] [Related]

  • 20. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M.
    Expert Opin Pharmacother; 2013 Jan 04; 14(1):123-36. PubMed ID: 23256518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.